Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company developing therapies for central and peripheral nervous system diseases, announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026. The meeting, held today, included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members.
The motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached. This outcome highlights the importance of shareholder participation in corporate governance decisions.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support.
Newron is focused on developing innovative therapies for central and peripheral nervous system diseases. Its lead compound, evenamide, is a first-in-class glutamate modulator being developed for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia, currently in the global pivotal ENIGMA-TRS Phase III program. Clinical results have shown significant improvements in efficacy measures over time with a favorable safety profile.
Newron has signed agreements with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and with Myung In Pharm for South Korea. Its first marketed product, Xadago®/safinamide, is approved for Parkinson's disease in multiple regions including the European Union, Switzerland, the UK, USA, Australia, Canada, and Japan. The product is commercialized by partner Zambon, with Supernus Pharmaceuticals holding U.S. rights and Meiji Seika responsible for Japan and other Asian territories.
For more information, visit www.newron.com.
